Cancer of unknown primary (CUP): Implementation of a robust pathway

Posted on 05/27/2025

There is a need to improve upon the diagnostic strategies for cancer of unknown primary ​(CUP) tumors​. And reducing delays in diagnosis and identifying patients at earlier stages may potentially ​improve patient outcomes. This guide aims to highlight key considerations to take into account when establishing a robust CUP pathway in academic and community centers across the US​.

View Resource

Jazz Pharmaceuticals Study for Adults Suffering from HER2-positive Biliary Tract Cancer

Posted on 05/14/2025

Jazz Pharmaceuticals is sponsoring a clinical study evaluating the safety and efficacy of an investigational medicine called zanidatamab for the treatment of advanced HER2-positive biliary tract cancer. Visit Biliary Tract Cancer Study - Inform Herizon BTC-302 Study - Jazz Pharmaceuticals or click the resource below to learn more.

View Resource

A Phase 3 Study of elacestrant versus standard endocrine therapy in node-positive ER+, HER2- early breast cancer with high risk of recurrence (ELEGANT)

Posted on 05/14/2025

Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine therapy in participants with node-positive ER+/HER2- early breast cancer with high risk of recurrence. The main purpose of this study is to compare the Invasive Breast Cancer-Free Survival (IBCFS) over a period of up to 5 years. 4220 participants will be included in this study around the world. Participants will have equal chance to be assigned to receive either of the treatment combinations.

Learn More

Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)

Published on: February 17, 2025

Watch Dr. David Sallman, a leading MDS specialist at the Moffitt Cancer Center, talk about the importance of investigating unexplained anemia.

View Resource Here

Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

Posted on 11.11.2024

Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i).
View Resource

ADC Cast is a Non-Promotional Educational Podcast Series Dedicated to Antibody Drug Conjugates (ADCs) in Breast Cancer

Posted on 10/16/2024

Hosted by Dr Javier Cortés and Prof. Peter Schmid, joined by an international panel of experts in ADCs and breast cancer, this educational podcast series unveils invaluable insights into ADCs, shedding light on their developmental history, their distinctive structural features and mechanisms of action, as well as potential future advancements.

Posted on 10/16/2024

Listen Here

What to Expect from Your Eye Care Appointments While Taking ELAHERE (mirvetuximab soravtansine-gynx)

Posted on 07.18.2024

This resource is intended for patients looking to:

• Understand what Ocular AEs may occur while on ELAHERE
• See what to expect during eye exams
• Review the important steps involved in proactively managing eye care while on treatment
• Learn the importance of communicating any side effects to your care team

Watch video

Best Practices for the Management of Ocular Adverse Events Associated with ELAHERE (mirvetuximab soravtansine-gynx)

Posted on 07.18.2024

This resource is intended for eye doctors or oncologists looking to:

• Understand why patients on ELAHERE require eye exams, and when
• Learn about what ocular AEs may be experienced by patients on ELAHERE
• Review the proactive eye drops administration patients should take during treatment
• See resources available to help facilitate communication between eye doctors and oncologists

Watch video

Help Patients Face the Realities of Life with Metastatic Breast Cancer Through Expose MBC

Published on: July 15, 2024

Gilead Oncology understands that metastatic breast cancer (MBC) is different from early breast cancer in many ways. Expose MBC is a platform for patients and their caregivers, friends, and family to share and gain honest information about their experiences, as well as to find resources, support, and community to help live their unique reality.

Visit http://Expose-MBC.com and share this site with your patients.

ESR1 Mutations in ER+/HER2 - Metastatic Breast Cancer

Published on: June 26, 2024

Nearly 1 out of 2 people with ER+/HER2- metastatic breast cancer may develop an ESR1 mutation after progression on hormone therapy.

Learn more about this ESR1 mutation at http://Knowesr1.com.